In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
New Scientist on MSN
I’m the first person whose life was saved by CRISPR base editing
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Riverside Homestead on MSNOpinion
A California wildfire hit 0% containment - then the forecast map already had the West marked, "Where the West might burn"
The strongest political angle is that ordinary people are being asked to absorb the cost and risk of systems they did not ...
CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Creative Biolabs is strengthening its lipid-based delivery portfolio with enhanced lipid nanoparticle (LNP) and liposome engineering capabilities designed to support the growing demand for RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results